Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT (Reuters) – German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *